CD19 and neoplasm: A landmark phase I/II trial of cord blood-derived CD19-directed CAR-NK cells reported a 73% (8/11) complete response rate in patients with CD19-positive lymphoid tumors, demonstrating that CAR-NK cells can also induce potent anti-tumor activity [8].